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Raji, a human I3 lymphoblastoid cell line has the ability to activate the complement cascade 
by alternate pathway mechanisms with subsequent fixation of C3 to receptors on the Raji cell 
membrane. Using this property, we examined the role that complement plays in mediating a 
cytolytic event between human peripheral blood monocytes and Raji cells coated with C3b, 
antibody, or both. Presence of C3 was confirmed by immune adherence. IgG bound to the Raji 
membrane was quantitated using I lz5 Staphylococcal protein A assay. The presence of 
alternate pathway-activated C3 on Raji cells failed to produce monocyte-mediated 
cytotoxicity. These same target cells subsequently coated with antibody concentration 
ranging from 200 to >600,000 SPA molecules per Raji cell produced neither enhancement nor 
inhibition of antibody-dependent, cell-mediated cytotoxicity (ADCC). ADCC was enhanced 
by complement when complement activation and binding of C3 to the cell surface occurred by 
classical pathway mechanisms. ADCC of 32% + 3.2 occurred with undiluted antiserum 
(625,000 SPA molecules bound/Raji cell) with enhancement to 52% ? 1.1 in the presence of 
C3. IgG inhibition of ADCC was unaffected by the presence of membrane-bound C3. 
INTRODUCTION 
Peripheral blood monocytes are the precursors of tissue macrophages and 
possess membrane receptors for the Fc region of IgG immunoglobulin (Fc receptor) 
and the third component of complement (C3) (1). The Fc receptor allows these cells 
to interact with antibody-coated red cells (2) and tumor cells (3) resulting in target 
cell damage and lysis. This reaction has been termed antibody-dependent, cellular 
cytotoxicity (ADCC) and several cell types which bear membrane Fc receptors can 
act as effector cells, i.e., granulocytes (4), monocytes (5), and K lymphocytes (6,7). 
The C3 receptor has been shown to be important in the ingestion of bacteria and 
other particles by granulocytes and macrophages (8). In addition, cells possessing 
the C3 receptor have the ability to bind or attach to C3-coated target cells (9). 
However, it is unclear whether this C3 receptor can trigger leukocyte-mediated, 
target cell damage and lysis. 
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Several studies have examined the interaction of lymphocytes with C3-coated, 
red cell targets and failed to demonstrate target cell damage (10, 11). However, 
Scornik has suggested that the lymphocyte C3 receptor may play a role in target cell 
lysis by preventing inhibition of ADCC by soluble immunoglobulin when target 
cells are coated by both IgG immunoglobulin and C3 (12). Kurlander has examined 
the interaction of blood monocytes with red cell targets coated with IgG 
immunoglobulin and/or C3 (13). They concluded that C3 on the target cell surface 
can enhance ADCC but not mediate cytolysis directly. 
No information exists on the role of C3 on tumor cell targets in regard to 
mediating cytolysis by monocytes or macrophages. We have chosen to examine the 
interaction of monocytes and tumor cells (Raji) coated with C3 in the presence or 
absence of cell-bound antibody. This B-cell lymphoblast cell line was chosen 
because it is capable of activating the alternate complement pathway resulting in 
C3-coated tumor cells independent of antibody (14, 15). 
METHODS 
Effector Cells 
Purified suspensions of blood monocytes were obtained from normal healthy 
donors as previously described (3). Briefly, mononuclear cell preparations obtained 
by Ficoll-Hypaque density centrifugation (16) were washed twice in RPMI- 10% 
fetal calf serum (FCS) and resuspended to a concentration of 15 x 10’Ymononuclear 
cells/ml. The 5-ml aliquots were added to Falcon 3003 tissue culture dishes and 
incubated for 90 min at 37°C in a humidified 95% air-5% COz atmosphere. These 
dishes were vigorously washed five times with RPMI-10% FCS to remove 
nonadherent cells. The adherent cells were exposed to ice cold Ca2+- and Mg2+-free 
buffer containing 0.2% bovine serum albumin and 0.1% EDTA for 30-45 set at 
which time the adherent cells were gently removed from the surface using a rubber 
policeman. These cells were then washed three times in RPMI-0.5% human serum 
albumin. Viabilities exceeded 90% by trypan blue exclusion and were greater than 
95% pure using latex ingestion, nonspecific esterase, and morphology as criteria. 
Target Cells 
Raji, a human B lymphoblastoid cell line derived from an individual with 
Burkitt’s lymphoma (17) was cultured in RPMI- 10% fetal calf serum supplemented 
with 0.3 mgml L-glutamine, 0.1 mg/ml gentamicin, and 100 units/ml penicillin. Raji 
cells were consistently used 48 to 72 hr after splitting of the culture and cell 
viabilities were always greater than 90% by trypan blue exclusion. The target cells 
were labeled with 51Cr (sodium chromate, New England Nuclear) as previously 
described (3). 
These cells were treated in a variety of ways to produce four different types of 
target cells. First, Raji cells coated with C3 alone via alternate pathway activation 
(14, 15) were prepared by incubation of 3 x lo6 cells with 60 ~1 of normal fresh 
serum or Cd-deficient serum (generously provided by Dr. Terrence Lee, 
Department of Medicine, University of North Carolina Medical School) for 20 min 
at 37°C. This dose of sera and time of incubation were selected by preliminary 
studies which demonstrated < 10% lysis (due to complement fixation) and strongly 
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positive immunoadherence assays. In general, the C-6-deficient sera gave stronger 
immunoadherence and less lysis of Raji cells. A second type of target cell was 
coated with antibody alone by incubating 10 x lo6 Raji cells with 100 ~1 of 
heat-inactivated immune rabbit antisera (3) or with 100 ~1 of several log dilutions of 
such antisera at 37°C for 45 min. The cells were washed and then ready for assay. A 
third target were Raji cells coated with C3 by alternate pathway activation (as 
above) and then coated with antibody by incubation with rabbit immune sera (or 
dilutions of immune sera). Finally, a fourth target preparation involved incubation 
of Raji cells with rabbit immune sera (as above) followed by incubation with the 
Cd-deficient serum (60 ~1/3 x 10” cells at 37°C for 20 min) which would allow C3 
attachment via classic pathway as well as alternate pathway. In all instances, the 
presence of C3 on the Raji cell surface was confirmed by immune adherence (IA) 
assay (15) and by reactivity with immunobeads coated with rabbit antihuman C3 
(Bio-Rad Laboratory, Richmond, Colo.). Control target cells included cells 
incubated in media alone or in heat-inactivated normal serum. 
Microcytotoxicity Assay 
Cytotoxicity assays were carried out as previously described (3) in Falcon 3040 
microtest II tissue culture plates. Triplicate cultures of 200,000 monocytes were 
co-incubated with 20,000 target cells (effector: target ratio of 10: 1) in a final volume 
of 300 ~1 (RPMI- 1640 with 10% FCS). Triplicate cultures of target cells alone were 
used to determine spontaneous release of 51Cr. The microtest plates were 
centrifuged at 608 for 4 min to initiate effector-target-cell interaction, and then 
incubated at 37°C in a humidified atmosphere of 95% air-5% COz for 4 hr. At the 
end of 4 hr, 100 ~1 of the supernatant was removed from each well to determine total 
supernate cpm (by multiplying x 3). Percentage cytotoxicity was calculated by the 
formula: 
A-B 
% cytotoxicity = - 
C 
x 100, 
A = mean cpm in supernate of wells containing target cells and monocytes, 
B = mean cpm in supernate of wells containing target cells alone, and C = mean 
total cpm of target cells added to each well. 
Determination of Immunoglobulin Bound to the Raji Cell Surface 
Quantitation of cell-bound antibody was assessed using 1125-labeled 
Staphylococcal protein A (SPA), a 42,500 molecular weight protein known to bind 
specifically to the Fc portion of IgG globulin (IgG& in man (19). Duplicate 
aliquots of 1 x lo6 cells were incubated with an excess (50 ng) of Ilz5-labeled SPA 
for 60 min at 25°C. The cells were then washed three times to remove unbound SPA. 
The counts per minute (cpm) bound to the cells were used to calculate the number of 
SPA molecules bound/cell as a quantitation of membrane-bound immunoglobulin. 
Prior studies indicated that 0.5-2 molecules of SPA bind/molecule IgG (19). 
Experiments to Characterize the Role of Complement on IgG Inhibition of ADCC 
We examined the competitive inhibition of ADCC by human immunoglobulin 
(purified human IgG, Miles Laboratory, Elkhart, Ind.) as previously described (3). 
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Appropriate concentrations of IgG were added to microwells containing monocytes 
and preincubated at 37°C for 30 min. Various types of target cells were then added 
and the assay was carried out in the usual fashion. 
RESULTS 
The Effect ofAlternate Pathway Activated Complement of Monocyte-Tumor-Cell 
Interaction 
As illustrated in Fig. 1, incubation of monocytes with Raji cells coated with C3 via 
alternate pathway activation produced no more Cr51 release than seen with control 
Raji cell preparations. This observation was true whether fresh normal or 
C6-deficient sera was used as a source of complement components. In addition, 
preparation of Raji cells coated with C3 via alternate pathway followed by 
sensitization with rabbit antisera produced no greater monocyte-mediated cytolysis 
than that seen with tumor cells coated with antibody alone (Fig. 1). In order to 
examine the effect of C3 on a broad range of antibody concentration on the cell 
surface, we sensitized the Raji cells following C3 attachment with serial log 
dilutions of our rabbit antisera. Figure 2 illustrates the broad range of cell-bound 
antibody which results from this type of antisera dilution as quantitated by the P5 
SPA radioimmunoassay for cell-bound antibody. As can be seen, the range of SPA 
molecule binding extends from 600,00O/cell (undiluted antisera) to 240kell (lo+ 
No Ab C’ Ab Ab+C’ 
FIG. 1. Effect of alternate pathway activated C3 on Raji cell interaction with monocytes. Monocyte 
mediated lysis of Raji lymphoblasts (no Ab), complement-coated Raji (C’), Raji cells sensitized with 
rabbit antiserum (Ab), and Raji cells initially treated with C6-deficient serum and subsequently 
sensitized with heat-inactivated rabbit antiserum (Ab + C’). 
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FIG. 2. The effect of antiserum dilution on Raji-bound IgG. Raji cells sensitized with logarithmic 
dilutions of antiserum and subsequently assessed for membrane-bound IgG in terms of number of 
molecules of radiolabeled SPA bound/target cell. 
dilution of antisera). Figure 3 illustrates that the degree of ADCC correlates with the 
degree of antibody sensitization and that the presence of C3 activated by alternate 
pathway does not alter the cytotoxicity seen with antibody alone. Again, Raji cells 
coated with C3 alone failed to result in significant degrees of cytolysis. 
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FIG. 3. The effect of alternate pathway activated complement on ADCC. Raji cells incubated with 
C6-deficient serum and then sensitized with varying dilutions of antiserum (open bars) were compared 
with Raji which were incubated with antiserum but not C6-deficient serum (hatched bars). Controls 
include Raji cells which were incubated with media alone (no Ab), heat-inactivated serum (HIS), and 
C6-deficient serum (C’). 
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Effect of Complement Activated via Classical Pathway on Monocyte ADCC 
In order to examine the effect of Raji cell-bound C3 activated via the classical 
pathway, cells were sensitized with varying dilutions of antibody and then 
incubated with C6-deficient serum as a source of complement components. 
Immune adherence assays for C3 were positive at all serum dilutions illustrated in 
Fig. 4. As can be seen in Fig. 4, the presence of C3 on the cell surface enhanced 
ADCC when target cells were sensitized with undiluted antisera, i.e., 32% + 3.2 to 
52% 2 1.1 (n = 3; P < 0.01). No enhancement was seen with sensitization of Raji 
cells at lower dilutions of antisera (target cells IA positive at all dilutions of 
antisera). 
These experiments were carried out 3 months after those illustrated in Fig. 3 and 
the lower degree of ADCC produced by the antisera is unexplained. Measurement 
of IgG-bound/Raji cell was identical to the curve illustrated in Fig. 2 so that change 
in degree of antibody sensitization does not account for the lower degree of ADCC. 
Effect of C3 on ZgG Inhibition of ADCC 
In order to determine whether the presence of C3 on the Raji cell surface could 
enhance monocyte-target-cell interaction which occurs during ADCC, we 
examined the effect of cell-bound C3 on the ability of soluble immunoglobulin to 
inhibit ADCC (3). As seen in Table 1, enhancement of cytolysis is seen when C3 is 
present on the Raji cell surface via classical pathway activation with undiluted 
antisera. However, no dramatic change occurred in the ability of soluble IgG to 
cause competitive inhibition of the ADCC reaction. Thus, comparable degrees of 
inhibition were seen with 1 and 10 mg/ml soluble IgG whether the target cells were 
coated with antibody and C3 or antibody alone. This was also true for IgG inhibition 
over the whole range of antisera listed in Fig. 4 (data not shown). 
DISCUSSION 
The presence of the third component of complement on the surface of various 
targets (bacteria and red cells) certainly plays an important role in phagocytosis of 
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FIG. 4. The effect of complement activated by classical pathway on ADCC. Raji targets initially 
sensitized with logarithmic dilutions of rabbit antiserum (hatched bars) were compared to similar targets 
subsequently exposed to C6-deficient serum (open bars). Controls are identical to those in Fig. 3. 
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TABLE 1 
Effect of C3 on IgG Inhibition of Monocyte ADCC” 
IgG concentration (&ml) 
Targets* 0 1 10 
Expt 1 T 3.9 4.7 5.6 
T-A 36.5 19.7 (46) 4.8 (87) 
T-A-C 51.2 25.8 (50) 14.9 (71) 
Expt 2 T 4.1 6.1 5.2 
T-A 33.8 15.6 (54) 6.2 (82) 
T-A-C 47.7 22.0 (54) 13.6 (71) 
n Values listed represent percentage cytotoxicity. The values in parentheses reflect the percentage 
inhibition of ADCC. 
* (T) Raji lymphoblasts, (T-A) Raji sensitized with undiluted antiserum, (T-A-C) Raji sensitized 
with undiluted antiserum followed by incubation with Cb-deficient serum. 
such targets by granulocytes and monocytes (8,9, 13). These effects are thought to 
be mediated by a membrane receptor for C3 on the surface of granulocytes and 
monocytes which can mediate binding of C3-coated targets to the effector cell 
surface (1,9). However, it is unclear whether this membrane receptor can mediate 
or trigger effector cell damage of bound but not ingested target cells. Several studies 
have examined red cell targets coated with C3 and were unable to demonstrate 
cytolysis by lymphocytes (10, 11) or monocytes (13). Our studies utilizing 
C3-coated lymphoblast target cells have similarly failed to demonstrate cytolysis by 
monocytes as well as human lymphocyte preparations (unpublished observations). 
A second role for the C3 receptor has been proposed in that it may act in concert 
with effector cell receptors for immunoglobulin and thus enhance the lytic potential 
toward red cell targets coated with IgG immunoglobulin and complement (10, 11, 
13). Indeed, we found definite enhancement of ADCC when C3 was activated on the 
target cell surface by large numbers of IgG although smaller amounts of antibody or 
binding of C3 by the alternate pathway of complement activation produced no 
change in ADCC. 
Finally, the C3 receptor has been reported to aid in cytolysis of red cells coated 
with antibody and C3 by preventing inhibition of lysis by competing immunoglobu- 
lin (12). We were unable to demonstrate this effect even using target cells coated 
with C3 to a degree which enhanced the ADCC event. 
Thus, our studies on the interaction of monocytes with C3-coated tumor cells are 
in keeping with several observations made using red cell targets in that we were 
unable to demonstrate direct cytolysis of targets coated with C3 alone and some 
enhancement of ADCC when C3 was present in optimal fashion. However, the lack 
of effect of C3 alone should be interpreted with caution. This could also reflect a 
quantitative or qualitative limitation of our ability to place C3 on the cell surface in 
the absence of IgG immunoglobulin. For example, several lymphoblast cell lines 
are capable of triggering the alternate pathway of complement activation and 
deposition of C3 on the surface of Raji cells is thought to be, at least in part, due to the 
presence of C3 receptor on the Raji cell surface (14,15). Thus, the orientation of the 
C3 molecule present may be less than optimal for subsequent interaction with the 
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monocyte C3 receptor despite the fact that these cells are strongly immune 
adherence positive. Similarly, the lack of C3 enhancement of ADCC at low 
dilutions of antisera may relate to quantitative changes in the amount of C3 on the 
target cell surface despite the fact that the cells were IA positive. 
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